Clearance of psoriasis with low dose cyclosporin

British Medical Journal (Clinical research ed.)

Volumn 293, Issue 6549, 1986, Pages 731-732

  Valdimarsson, H ^b   Powles, A V ^a   Leonard, J N ^a   Fry, L ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Department of Immunology ^*  (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 2; METHOTREXATE; METHOXSALEN; RAZOXANE;

DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG THERAPY; HUMAN; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; INTOXICATION; KIDNEY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; PUVA; THERAPY;

ADULT; CYCLOSPORINS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS;

EID: 0022921096     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.293.6549.731     Document Type: Article

References (4)

1. Baker B., Swain A.F., Valdimarsson H., et al. T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol 1984;110:37–44.
2. Baker B., Swain A.F., Fry L., et al. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984;110:555–64.
3. Valdimarsson H., Baker B.S., Jonsdottir I., Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunology Today (in press).
4. Bendtzen K., Tvede N., Svensen H. Ciclosporin (cyclosporin A): molecular biology and clinical use. International Research Communications Service Medical Science 1984;12:874–6.